These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 23363670)
1. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome]. Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670 [TBL] [Abstract][Full Text] [Related]
2. Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention. Tang XF; Wang J; Zhang JH; Meng XM; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yuan JQ; Yang YJ Eur J Clin Pharmacol; 2013 May; 69(5):1103-12. PubMed ID: 23150151 [TBL] [Abstract][Full Text] [Related]
3. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091 [TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC; Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498 [TBL] [Abstract][Full Text] [Related]
5. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. Wu H; Qian J; Sun A; Wang Q; Ge J Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905 [TBL] [Abstract][Full Text] [Related]
6. Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention. Rideg O; Komócsi A; Magyarlaki T; Tokés-Füzesi M; Miseta A; Kovács GL; Aradi D Pharmacogenomics; 2011 Sep; 12(9):1269-80. PubMed ID: 21806387 [TBL] [Abstract][Full Text] [Related]
7. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970 [TBL] [Abstract][Full Text] [Related]
8. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
9. CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Chan MY; Tan K; Tan HC; Huan PT; Li B; Phua QH; Lee HK; Lee CH; Low A; Becker RC; Ong WC; Richards MA; Salim A; Tai ES; Koay E Pharmacogenomics; 2012 Apr; 13(5):533-42. PubMed ID: 22462746 [TBL] [Abstract][Full Text] [Related]
10. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
11. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease. Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487 [TBL] [Abstract][Full Text] [Related]
12. PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Li X; Zhang L; Chen X; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Xu Q; Zhang Y; Li Y; Lu C; Yin T Thromb Res; 2013 Oct; 132(4):444-9. PubMed ID: 23993903 [TBL] [Abstract][Full Text] [Related]
13. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042 [TBL] [Abstract][Full Text] [Related]
14. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. Peng W; Shi X; Xu X; Lin Y Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608 [TBL] [Abstract][Full Text] [Related]
15. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel]. Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044 [TBL] [Abstract][Full Text] [Related]
16. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis. Jiang M; You JH Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429 [TBL] [Abstract][Full Text] [Related]
17. Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. Wu H; Qian J; Xu J; Sun A; Sun W; Wang Q; Ge J Int J Cardiol; 2013 Apr; 165(1):204-6. PubMed ID: 22974728 [No Abstract] [Full Text] [Related]
18. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404 [TBL] [Abstract][Full Text] [Related]
19. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494 [TBL] [Abstract][Full Text] [Related]
20. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]